How to State Destination-Market Requirements in a Peptide RFQ

A peptide RFQ should give the supplier enough regulatory context to quote the right documentation scope. If the RFQ only says molecule, vial size, and quantity, the supplier may quote a basic chemical release packet when the buyer actually needs pharmacy, distributor, or destination-market support.

How should destination-market regulatory requirements be stated in a peptide RFQ?

State the destination country, buyer type, intended regulatory pathway, route of use, dosage-form context, required release tests, import-document needs, and whether audit support is required. The supplier should be able to confirm what is standard, what is an add-on, and what cannot be supported before a price is accepted.

RFQ fields that prevent rework

• Destination country or region
• Buyer type: 503A, 503B, EU compounder, licensed distributor, research organization, or OEM
• Intended route and risk context: topical, oral, in vivo, injectable, or pharmacy workflow
• Required documents: COA, HPLC, MS, LAL, microbial limits, stability, SDS, method details, audit support
• Import or resale constraints: importer of record, license status, customs documents, language requirements
• Timeline: sample packet, pilot lot, recurring forecast, and first shipment target

Why this matters

The RFQ determines the analytical scope. A supplier may be able to add LAL, microbial limits, stability, or audit-support documents, but those tests change lead time and cost. Naming the destination-market requirement early lets QA and commercial teams align the quote with the actual buyer risk rather than revising the packet after PO.